Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) Shares Outstanding (Weighted Average) (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $732.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 2255.59% year-over-year to $732.9 million, compared with a TTM value of $732.9 million through Nov 2025, up 2255.59%, and an annual FY2025 reading of $90.6 million, up 199.69% over the prior year.
  • Shares Outstanding (Weighted Average) was $732.9 million for Q4 2025 at CNBX Pharmaceuticals, up from $90.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $732.9 million in Q4 2025 and bottomed at $1.1 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $73.4 million, with a median of $30.6 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) tumbled 99.17% in 2022, then soared 2255.59% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $131.1 million in 2021, then tumbled by 99.04% to $1.3 million in 2022, then surged by 2106.87% to $27.8 million in 2023, then increased by 12.07% to $31.1 million in 2024, then skyrocketed by 2255.59% to $732.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CNBX at $732.9 million in Q4 2025, $90.6 million in Q3 2025, and $35.5 million in Q2 2025.